Patients’ and dermatologists’ preferences in artificial intelligence–driven skin cancer diagnostics: A prospective multicentric survey study - 22/05/24
Doi : 10.1016/j.jaad.2024.04.033
Sarah Haggenmüller, MSc a, Roman C. Maron, MSc a, Achim Hekler, MSc a, Eva Krieghoff-Henning, PhD a, Jochen S. Utikal, MD b, c, d, Maria Gaiser, MD b, c, d, Verena Müller, MD b, c, d, Sascha Fabian, PhD e, Friedegund Meier, MD f, Sarah Hobelsberger, MD f, Frank F. Gellrich, MD f, Mildred Sergon, MD f, Axel Hauschild, MD g, Michael Weichenthal, MD g, Lars E. French, MD h, i, Lucie Heinzerling, MD h, k, Justin G. Schlager, MD h, Kamran Ghoreschi, MD j, Max Schlaak, MD j, Franz J. Hilke, PhD j, Gabriela Poch, MD j, Sören Korsing, MD j, Carola Berking, MD k, Markus V. Heppt, MD k, Michael Erdmann, MD k, Sebastian Haferkamp, MD l, Konstantin Drexler, MD l, Dirk Schadendorf, MD m, Wiebke Sondermann, MD m, Matthias Goebeler, MD n, Bastian Schilling, MD n, Jakob N. Kather, MD o, Stefan Fröhling, MD p, Katharina Kaminski q, Astrid Doppler q, Tabea Bucher, MSc a, Titus J. Brinker, MD a, ⁎ 
Collaborators
Carina Nogueira Garcia, Janis Thamm, Sandra Schuh, Julia Welzel, Lara Valeska Maul-Duwendag, Paul Georg, Laurence Feldmeyer, Falk Bechara, Julian Steininger, Sophia Lehr, Ricarda Rauschenberg, Anna-Lisa Eberle, Sören Manfred Hartmann, Helena Hasler, Sophia Bender-Säbelkampf, Jürgen P. Bauerschmitz, Matthias Kaufmann, Cornelia Erfurt-Berge, Wiebke Katharina Peitsch, Ulrike Wehkamp, Marion Jost, Cindy Franklin, Julia Holzgruber, Maximilian Haist, Mario Giulini, Sebastian Wohlfeil, Valentina Faihs, Elke Sattler, Suzan Stürmer, Sebastian Krammer, Benjamin Kendziora, Semra Larissa Akcetin, Mohammed Mitwalli, Pinar Avci, Zeno Fiocco, Daniela Hartmann, Manuel Pedro Fernandes Lobo Pereira, Alexander Thiem, Valentin Aebischer, Stephan Forchhammer, Isabel Wolff
a Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany
b Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, Germany
c Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany
d DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany
e Department of Economics, University of Applied Science Neu-Ulm, Neu-Ulm, Germany
f Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany and Skin Cancer Center at the University Cancer Centre Dresden and National Center for Tumor Diseases, Dresden, Germany
g Department of Dermatology, University Hospital (UKSH), Kiel, Germany
h Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany
i Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida
j Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
k Department of Dermatology, University Hospital Erlangen, Comprehensive Cancer Center Erlangen – European Metropolitan Region Nürnberg, CCC Alliance WERA, Erlangen, Germany
l Department of Dermatology, University Hospital Regensburg, Regensburg, Germany
m Department of Dermatology, University Hospital Essen, Essen and German Cancer Consortium, partner site Essen and National Center for Tumor Diseases (NCT), NCT-West, Campus Essen and University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany
n Department of Dermatology, Venereology and Allergology, University Hospital Würzburg and National Center for Tumor Diseases (NCT) WERA, Würzburg, Germany
o Else Kroener Fresenius Center for Digital Health, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany
p Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany
q Melanom Info Deutschland – MID e.V., Essen, Germany
∗Correspondence to: Titus J. Brinker, MD, Digital Biomarkers for Oncology Group, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, GermanyDigital Biomarkers for Oncology GroupGerman Cancer Research Center (DKFZ)Im Neuenheimer Feld 280Heidelberg69120Germany
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Wednesday 22 May 2024
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Key words : acceptance, artificial intelligence, dermatologist view, dermatology, melanoma, patient view, skin cancer, survey study
Plan
| Funding sources: This study was funded by the Federal Ministry of Health, Berlin, Germany (grant: Skin Classification Project 2 [SCP2]; grant holder: Titus J. Brinker, German Cancer Research Center, Heidelberg, Germany), the Ministry of Social Affairs, Health and Integration of the Federal State Baden-Württemberg, Germany (grant: AI-Translation-Initiative [KTI]; grant holder: Titus J. Brinker, German Cancer Research Center, Heidelberg, Germany), and the Studienstiftung des deutschen Volkes, Bonn, Germany (scholarship holder: Sarah Haggenmüller). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Dr Utikal has received travel support from Amgen, Bristol Myers Squibb, GSK, Immunocore, LeoPharma, Merck Sharp and Dohme, Novartis, Pierre Fabre, Roche, and Sanofi outside the submitted work. Dr Meier has received travel support from Novartis, Roche, BMS, MSD, and Pierre Fabre and research funding from Novartis and Roche. Dr Hobelsberger reports clinical trial support from Almirall and has received travel support from the following companies: UCB, Janssen Cilag, Almirall, Novartis, Lilly, LEO Pharma, and AbbVie outside the submitted work. Gellrich has received travel support from Sun Pharma, Sanofi, and Merck. Dr Erdmann declares travel support from Bristol-Meyers Squibb, Immunocore, and Novartis outside the submitted work. Dr Hauschild reports clinical trial support from the following companies: Agenus, Amgen, BMS, Dermagnostix, Highlight Therapeutics, Immunocore, Incyte, IO Biotech, MerckPfizer, MSD, NercaCare, Novartis, Philogen, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme, Seagen, Sun Pharma, and Xenthera, outside the submitted work. Dr Schilling reports research funding from BMS, Pierre Fabre Pharmaceuticals, and MSD and travel support from Novartis, Roche, BMS, Pierre Fabre Pharmaceuticals, and Amgen, outside the submitted work. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Not applicable (anonymous survey study). |
© 2024
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?